Is Aclaris Therapeutics Inc (ACRS) overvalued? · rev $18.7M
Aclaris Therapeutics Inc (ACRS) is a biotechnology company listed on NASDAQ.
This page asks whether Aclaris Therapeutics Inc (ACRS) looks expensive on cached numbers — not a short thesis.
Latest reported ACRS revenue for 2024-12-31 was $18.7M. Net income was -$132.1M. Revenue was down 40.1% from 2023-12-31 to 2024-12-31. ACRS currently screens at market cap $615.9M.
ACRS currently screens at market cap $615.9M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ACRS 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ACRS stock page for the full model, not this heading.
Not investment advice.